



UnitedHealthcare Pharmacy  
Clinical Pharmacy Programs

Program Number	2023 P 2127-7
Program	Prior Authorization/Medical Necessity
Medication	Emflaza <sup>®</sup> (deflazacort)
P&T Approval Date	5/2017, 10/2018, 10/2019, 10/2020, 10/2021, 10/2022, 10/2023
Effective Date	1/1/2024

**1. Background:**

Emflaza (deflazacort) is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.<sup>1</sup>

In a report from the Guideline Development Subcommittee of the American Academy of Neurology, regarding selection of prednisone versus deflazacort in the treatment of DMD, the following statement is made: “prednisone and deflazacort are possibly equally effective for improving motor function in patients with DMD (2 Class III studies). There is insufficient evidence to directly compare the effectiveness of prednisone vs deflazacort in cardiac function in patients with DMD (1 Class III study of a combined cohort).<sup>2</sup> The UnitedHealthcare Pharmacy and Therapeutics Committee has determined that Emflaza is Therapeutically Equivalent to prednisone in the treatment of DMD.

**2. Coverage Criteria<sup>a</sup>:**

**A. Duchenne Muscular Dystrophy**

1. Published clinical evidence shows Emflaza is likely to produce equivalent therapeutic results as other available corticosteroids (e.g., prednisone); therefore, Emflaza is **not medically necessary** for treatment of Duchenne muscular dystrophy.

<sup>a</sup> State mandates may apply. Any federal regulatory requirements and the member specific benefit plan coverage may also impact coverage criteria. Other policies and utilization management programs may apply.

**3. Additional Clinical Rules:**

- Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic. Use of automated approval and re-approval processes varies by program and/or therapeutic class.

**4. References:**

1. Emflaza [package insert]. PTC Therapeutics Inc. June 2021.
2. Gloss D, Moxley III R, Ashwal S, et. al. Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology* 2016; 86;465-472.



Program	Prior Authorization/Medical Necessity - Emflaza (deflazacort)
<b>Change Control</b>	
5/2017	New program
10/2018	Annual review. No changes to criteria. Updated references.
10/2019	Annual review. Updated background updating indication in patients 2 years and older. Updated reference.
10/2020	Annual review with no changes to clinical coverage criteria. Updated references.
10/2021	Annual review with no changes to clinical coverage criteria. Updated references.
10/2022	Annual review with no changes to clinical coverage criteria.
10/2023	Annual review with no changes to coverage criteria.